Takeda Pharmaceutical Reports Q1 Fiscal 2026 Results in Line With Guidance
Takeda Pharmaceutical (NYSE:TAK) reported first-quarter fiscal 2026 results that aligned with its full-year outlook. Revenue reached JPY 1.22 trillion, showing a 10.2% increase on an actual foreign-exchange basis but declining slightly by 0.5% at constant exchange rates. Core operating profit rose to JPY 358.9 billion, up 11.5% in FX terms and down 0.5% at constant rates. The company attributed growth primarily to core brands like ENTYVIO and new product launches such as FRUZAQLA and LIVTENCITY, which offset declines from mature products and generic competition for Vyvanse. Takeda maintained its full-year guidance unchanged and expects JPY 650 billion to JPY 750 billion in free cash flow. Looking ahead, the company is preparing three key product launches: ORZEYFUL for narcolepsy type 1 (approved in China), rusfertide for polycythemia vera, and zasocitinib for psoriasis. Takeda now holds exclusive global rights to rusfertide after a $200 million payment to Protagonist.
Tickers: $TAK
Topics: financial results foreign exchange impact pharmaceuticals